發(fā)布時間：2018-05-03 00:29

  本文選題：內(nèi)鏡逆行胰膽管造影術(shù) + 膽總管結(jié)石��； 參考：《中國藥房》2017年14期

【摘要】：目的:評價生長抑素、烏司他丁、奧曲肽和加貝酯預防膽總管結(jié)石患者內(nèi)鏡逆行胰膽管造影(ERCP)術(shù)后高淀粉酶血癥和胰腺炎的經(jīng)濟性。方法:收集我院2008年7月-2016年4月經(jīng)ERCP診療的316例膽總管結(jié)石患者的病歷資料,按蛋白酶抑制劑使用情況分成空白對照組(58例)、生長抑素組(64例)、烏司他丁組(65例)、奧曲肽組(68例)和加貝酯組(61例)。ERCP術(shù)前,空白對照組患者給予禁食、靜脈營養(yǎng)支持、抑酸等常規(guī)治療;在此基礎上,其余4個藥物組患者均于手術(shù)前6 h開始按照說明書進行預防用藥。比較5組患者ERCP術(shù)后高淀粉酶血癥和胰腺炎的發(fā)生率,術(shù)后3、24、48 h視覺模擬法(VAS)評分,以及不良反應發(fā)生情況。采用成本-效果分析法評定各組治療方案的經(jīng)濟性。結(jié)果:與空白對照組比較,生長抑素組、烏司他丁組、奧曲肽組和加貝酯組患者的住院時間顯著縮短,高淀粉酶血癥和胰腺炎的發(fā)生率顯著降低,術(shù)后3、24、48 h的VAS評分顯著降低,差異均有統(tǒng)計學意義(P0.05)。4個藥物組之間比較,上述考察指標均無明顯差異,不良反應發(fā)生率均較低且差異無統(tǒng)計學意義(P0.05)。生長抑素組的成本-效果比最低,最具有成本效果優(yōu)勢;增量成本-效果比及敏感度分析結(jié)果也證實此結(jié)果。結(jié)論:生長抑素、烏司他丁、奧曲肽和加貝酯均能有效預防ERCP術(shù)后高淀粉酶血癥和胰腺炎的發(fā)生,減輕患者疼痛,并具有較高的安全性。其中,生長抑素能以最低成本取得最佳療效,為抑制ERCP術(shù)后高淀粉酶血癥和胰腺炎的最合理方案。
[Abstract]:Objective: to evaluate the effect of somatostatin, ulinastatin, octreotide and Gabectin on the prevention of hyperamylase and pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in patients with choledocholithiasis. Methods: the medical records of 316 cases of choledocholithiasis diagnosed and treated by ERCP from July 2008 to April 2016 in our hospital were collected. According to the usage of protease inhibitor, the patients were divided into control group (n = 58), somatostatin group (n = 64), urinastatin group (n = 65) and octreotide group (n = 68). On the basis of this, the patients in the other 4 groups were treated with prophylaxis according to the instructions 6 hours before operation. The incidence of hyperamylase and pancreatitis, visual analogue visual analogue (vas) score and adverse reaction were compared in 5 groups after ERCP. The cost-effect analysis was used to evaluate the economy of each group. Results: compared with the blank control group, the hospitalization time of the patients in the somatostatin group, ulinastatin group, octreotide group and Gabexate group was significantly shortened, the incidence of hyperamylase and pancreatitis was significantly decreased, and the VAS score at 3244h after operation was significantly decreased. The differences were statistically significant (P 0.05). There was no significant difference in the above indexes among the four drug groups, and the incidence of adverse reactions was lower and there was no significant difference in the incidence of adverse reactions (P 0.05). The cost-effect ratio of somatostatin group was the lowest, and the cost effect advantage was the most, and the incremental cost-effect ratio and sensitivity analysis also confirmed the result. Conclusion: somatostatin, ulinastatin, octreotide and Gabectin can effectively prevent the occurrence of hyperamylase and pancreatitis after ERCP, relieve pain and have high safety. Among them, somatostatin can obtain the best curative effect at the lowest cost. It is the most reasonable scheme to inhibit hyperamylase and pancreatitis after ERCP.
【作者單位】： 萍鄉(xiāng)市人民醫(yī)院/贛南醫(yī)學院附屬萍鄉(xiāng)醫(yī)院消化內(nèi)科;
【基金】：國家自然科學基金資助項目(No.81360080)
【分類號】：R575.7;R576

【相似文獻】

相關(guān)期刊論文 前10條

1 吳東;劉曉紅;;慢性高淀粉酶血癥[J];中國實用內(nèi)科雜志;2007年19期

2 袁建軍;;高淀粉酶血癥98例病因分析[J];中外醫(yī)學研究;2012年32期

3 林華征;;糖尿病酮癥酸中毒合并高淀粉酶血癥的回顧性分析[J];實用糖尿病雜志;2013年04期

4 吳鋒;劉姍;毛建生;何雪云;林海;;依普比善預防內(nèi)鏡逆行胰膽管造影術(shù)后胰腺炎及高淀粉酶血癥臨床分析[J];實用醫(yī)學雜志;2008年01期

5 葉慶艾;;非胰腺原性的原因不明的慢性高淀粉酶血癥[J];國外醫(yī)學(內(nèi)科學分冊);1981年07期

6 張連鳳;高淀粉酶血癥的鑒別試驗[J];國外醫(yī)學.臨床生物化學與檢驗學分冊;1987年05期

7 周麗雅,李柯;急性胰腺炎的診治要點 高淀粉酶血癥[J];醫(yī)師進修雜志;2004年17期

8 王p，

本文編號：1836154